Search form

Sections

Carl Elliott

Q&A with Leigh Turner, Part 3: Celltex Tries to Intimidate a Whistleblower

Bioethicist Leigh Turner describes how the stem cell company Celltex tried to intimidate him and his university when he asked the FDA to investigate the company.

Q&A with Leigh Turner, Part 2: Finding Ethical Quandaries Amid Academic Rivalries

Bioethicist Leigh Turner talks about why he sicced the FDA on Celltex and about academic rivalries in the world of bioethics.

Q&A with Leigh Turner: Tracking Medical Tourism Consequences

Bioethicist Leigh Turner, recently under fire from a stem cell company he criticized for ethical problems, talks about his research on medical tourism.

Slap: Celltex Threatens University of Minnesota For Ethicist's FDA Letter

When controversial bioethicist Glenn McGee quit his job as chief ethics advisor to Houston-based Celltex Therapeutics in February, the controversy over the company was on the verge of dying down. Until Celltex threatened a major public university and the very concept of free speech.

Slap: Pressure From Politically-Connected Stem Cell Firm Celltex Leads To Slate Retraction

Why did Slate retract a critical commentary by bioethicist Carl Elliott on stem cell firm Celltex after a demand by the controversial company's CEO?

The Markingson Files: Court leaves key questions in clinical trial suicide unanswered

Any investigative reporter will tell you that a case dismissal does not necessarily mean a victory. Here's how that rule of thumb figures into the case of Dan Markingson, who committed suicide after participating in a clinical trial for the psychiatric drug Seroquel.

The Markingson Files: University of Minnesota dallies on clinical trial documentation

A candid email from a university publicist sheds some, but not enough, light on why the university won't provide documents from a controversial Seroquel clinical study.

The Markingson Files: Conflicts of interest in clinical trials should be transparent

It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.

The Markingson Files: Why health writers should track the money behind medical studies

One of the biggest oversights a health writer can make is to cover a scientific study and not talk about its funders. William Heisel examines what can happen when a study's funding is overlooked.

The Markingson Files: Can pressure to recruit patients subvert a clinical trial?

Bioethicist and writer Carl Elliott used many documents to piece together the story of how a research team desperate for patients helped create a pipeline for clinical trial participants by setting up a psychiatric ward. Here's how he did it.

Pages

Announcements

New this year: a $1,000 reporting stipend! Apply now for the all-expenses-paid 2015 California Health Journalism Fellowship and spend five days in Los Angeles March 1-5, 2015 learning about how Obamacare is -- and isn't -- working for Californians and what other factors, besides health care access, contribute to good health.  

CONNECT WITH THE COMMUNITY

Member Activities

Lee Adcock has shared a story

Read it.

Minnur Yunusov's profile has been updated

Connect with Minnur Yunusov

Ruxandra Guidi has shared a microsite blog

Read it.

Anna Romano has shared a blog post

Read it.

Ryan White has shared a blog post

Read it.
More Member Activities

Follow Us

ReportingHealth

Reporting on Underserved Communities



How can journalists and foundations collaborate to deepen and improve reporting on underserved communities? Our USC Annenberg School of Journalism program in collaboration with The California Endowment, the Wyncote Foundation and Media Impact Funders, convened 75 leaders from both fields.

Read More »